Michelle Lockhart

1.2k total citations
16 papers, 961 citations indexed

About

Michelle Lockhart is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Neurology. According to data from OpenAlex, Michelle Lockhart has authored 16 papers receiving a total of 961 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 4 papers in Cellular and Molecular Neuroscience and 4 papers in Neurology. Recurrent topics in Michelle Lockhart's work include Pharmaceutical Economics and Policy (4 papers), Pharmaceutical industry and healthcare (2 papers) and Neurological disorders and treatments (2 papers). Michelle Lockhart is often cited by papers focused on Pharmaceutical Economics and Policy (4 papers), Pharmaceutical industry and healthcare (2 papers) and Neurological disorders and treatments (2 papers). Michelle Lockhart collaborates with scholars based in New Zealand, United Kingdom and Australia. Michelle Lockhart's co-authors include Kenneth M. Taylor, Christopher Frampton, Michael P. Murphy, Robin A.J. Smith, Barry Snow, John D. O’Sullivan, Victor S.C. Fung, Geraldine F. Keogh, Frank Weilert and Edward Gane and has published in prestigious journals such as Journal of Hepatology, International Journal of Environmental Research and Public Health and Movement Disorders.

In The Last Decade

Michelle Lockhart

16 papers receiving 950 citations

Peers

Countries citing papers authored by Michelle Lockhart

Since Specialization

Citations

This map shows the geographic impact of Michelle Lockhart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle Lockhart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle Lockhart more than expected).

Fields of papers citing papers by Michelle Lockhart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle Lockhart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle Lockhart. The network helps show where Michelle Lockhart may publish in the future.

Co-authorship network of co-authors of Michelle Lockhart

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle Lockhart. A scholar is included among the top collaborators of Michelle Lockhart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle Lockhart. Michelle Lockhart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Development of subfamily-based consensus PCR assays for the detection of human and animal herpesviruses 2023 ·European Journal of Clinical Microbiology & Infectious Diseases ·(unknown), Michelle Lockhart, (unknown), David Whitmore, Ellen Ariel, Jeff Butler, Paul F. Horwood	3
2	Safety and acceptability of clozapine and risperidone in progressive multiple sclerosis: a phase I, randomised, blinded, placebo-controlled trial 2020 ·BMJ Neurology Open ·Anne Camille La Flamme, David Abernethy, Dalice Sim, (unknown), Michelle Lockhart, David Bourke, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Bronwen Connor	9
3	A long-term follow-up of safety and clinical efficacy of NTCELL® [Immunoprotected (Alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease 2020 ·Parkinsonism & Related Disorders ·Eoin Mulroy, Barry Snow, Arnold Bok, M. P. Simpson, A. J. Smith, Kenneth M. Taylor, Michelle Lockhart, Benjamin Lam, Christopher Frampton, (unknown), Patrick Schweder, Benson Chen, (unknown), (unknown)	11
4	Barkhausen noise as an intrinsic fingerprint for ferromagnetic components 2018 ·Smart Materials and Structures ·David Mascareñas, Michelle Lockhart, Thomas J. Lienert	2
5	A phase IIb, randomised, double-blind, placebo-controlled, dose-ranging investigation of the safety and efficacy of NTCELL® [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease 2018 ·Parkinsonism & Related Disorders ·Barry Snow, (unknown), Arnold Bok, M. P. Simpson, A. J. Smith, Kenneth M. Taylor, Michelle Lockhart, (unknown), Christopher Frampton, Patrick Schweder, Benson Chen, (unknown), (unknown), (unknown)	34
6	Ascending Single‐Dose, Double‐Blind, Placebo‐Controlled Safety Study of Noribogaine in Opioid‐Dependent Patients 2016 ·Clinical Pharmacology in Drug Development ·Paul Glue, Gavin Cape, (unknown), Michelle Lockhart, Fred C. Lam, Noelyn Hung, (unknown), (unknown), (unknown), R. S. Crockett, John F. Howes, Börje Darpö, Meijian Zhou, (unknown), Lawrence Friedhoff	45
7	Switching Opioid‐Dependent Patients From Methadone to Morphine: Safety, Tolerability, and Methadone Pharmacokinetics 2016 ·The Journal of Clinical Pharmacology ·Paul Glue, Gavin Cape, (unknown), Michelle Lockhart, Fred C. Lam, Andrew Gray, Noelyn Hung, (unknown), (unknown), (unknown), John F. Howes, (unknown), Lawrence Friedhoff	11
8	Ascending-dose study of noribogaine in healthy volunteers: Pharmacokinetics, pharmacodynamics, safety, and tolerability 2014 ·The Journal of Clinical Pharmacology ·Paul Glue, Michelle Lockhart, Fred C. Lam, Noelyn Hung, (unknown), Lawrence Friedhoff	47
9	New Zealand’s Drug Development Industry 2013 ·International Journal of Environmental Research and Public Health ·Michelle Lockhart, Zaheer‐Ud‐Din Babar, Chris Carswell, Sanjay Garg	7
10	A randomised single‐blind comparison of the effectiveness of T ristel F use (chlorine dioxide) as an office‐based fluid soak, with C idex OPA ( ortho ‐phthaldehyde) using an automated endoscopic reprocessor ( AER ) as high‐level disinfection for flexible cystoscopes 2013 ·British Journal of Urology ·Peter Gilling, (unknown), Michael Addidle, Michelle Lockhart, Christopher Frampton, Mark R. Fraundorfer	2
11	New Zealand's drug development industry--strengths and opportunities. 2010 ·PubMed ·Michelle Lockhart, (unknown), Sanjay Garg	3
12	The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients 2010 ·Liver International ·Edward Gane, Frank Weilert, David Orr, Geraldine F. Keogh, Michael Gibson, Michelle Lockhart, Christopher Frampton, Kenneth M. Taylor, Robin A.J. Smith, Michael P. Murphy	309
13	A double‐blind, placebo‐controlled study to assess the mitochondria‐targeted antioxidant MitoQ as a disease‐modifying therapy in Parkinson's disease 2010 ·Movement Disorders ·Barry Snow, (unknown), Michelle Lockhart, Christopher Frampton, John D. O’Sullivan, Victor S.C. Fung, Robin A.J. Smith, Michael P. Murphy, Kenneth M. Taylor, (unknown)	458
14	Evaluation of policies to support drug development in New Zealand 2010 ·Health Policy ·Michelle Lockhart, (unknown), Sanjay Garg	9
15	Clinical trials in New Zealand: Progress, people, and policies 2010 ·Drug Development Research ·Michelle Lockhart, Zaheer‐Ud‐Din Babar, Sanjay Garg	1
16	847 PHASE II STUDY OF THE MITOCHONDRIAL ANTIOXIDANT MITOQUINONE FOR HEPATITIS C 2008 ·Journal of Hepatology ·Edward Gane, Douglas Orr, Frank Weilert, Geraldine F. Keogh, (unknown), Michael P. Murphy, Robin A.J. Smith, Michelle Lockhart, Chris Frampton, Kenneth M. Taylor	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact